Cantor Fitzgerald Reiterates “Neutral” Rating for Prothena (NASDAQ:PRTA)
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Friday,Benzinga reports. Several other analysts have also recently commented on PRTA. Piper Sandler dropped their target price on shares of Prothena from $110.00 to $81.00 and set an […]
Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Friday,Benzinga reports. Several other analysts have also recently commented on PRTA. Piper Sandler dropped their target price on shares of Prothena from $110.00 to $81.00 and set an […]
